Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Vandetanib
85
CHF
CHF 85.00
In stock
SYN-1090-M0011 mgCHF 85.00
SYN-1090-M0055 mgCHF 114.00
SYN-1090-M01010 mgCHF 142.00
SYN-1090-M05050 mgCHF 355.00
SYN-1090-M100100 mgCHF 553.00
| Product Details | |
|---|---|
| Synonyms | ZD6474; Zactima; Vandetanib |
| Product Type | Chemical |
| Properties | |
| Formula | C22H24BrFN4O2 |
| MW | 475.4 |
| CAS | 443913-73-3 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: EGFR - HER2 | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | UHTHHESEBZOYNR-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Vandetanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR, IC(50) of 40nM) and the epidermal growth factor receptor (EGFR).
Product References
- ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases: F. Carlomagno, et al.; Cancer Res. 62, 7284 (2002)